Conferences

Coverage from professional conferences related to lung cancer.

NSCLC

Promising Survival in Patients with Stage III NSCLC Treated with 74 GyE Proton Therapy/Chemotherapy Presenter: Joe Chang Presenter's Institution: University of Texas M.D. Anderson Cancer Center Background Non-Small Cell Lung Cancer (NSCLC) is a common and deadly disease, and treatment is associated with significant toxicity. Over 200,000 cases are diagnosed per year in the U.S., and over 160,000 deaths occur. For
Randomized Prospective Comparison of Adjuvant Mediastinal Radiation (RT) with or without Concurrent Chemotherapy with Cisplatin and Etoposide (PE) for Patients with Completely Resected T1-3N1-2M0 Non-Small Cell Lung Cancer (NSCLC): US Presenter: Keller SM et al Affiliation: Beth Israel Medical Center Summary:Multiple retrospective reviews as well as the prospective study from the Lung Cancer Study Group have demonstrated a local control advantage to adjuvant radiation therapy for NSCLC. However, the overwhelming pattern of failure remains distant. This trial was initiated
Chemoradiation With or Without Surgery for Stage IIIA Non-Small Cell Lung Cancer (NSCLC): A Comparison of Survival and Patterns of Failure Presenter: Mitchell Machtay, MD Affiliation: University of Pennsylvania Background:One of the most controversial topics in the management of NSCLC is the treatment of stage IIIA disease. Chemotherapy is generally accepted as an indicated treament in patients with good performance status. The management of local disease using surgery versus
Sequential Vs. Concurrent Chemotherapy and Radiation Therapy for Inoperable Non-Small Cell Lung Cancer (NSCLC) Analysis of Failures in a Phase III Study (RTOG 9410) Presenter: R. Komaki, MD Affiliation: University of Texas MD Anderson Cancer Center Summary: Since the randomized trial reported by Dillman et al., the standard of care for the treatment of unresectable or inoperable non small cell lung cancer in patients with a good performance status has been sequential chemotherapy
Phase III Comparison of Sequential vs Concurrent Chemoradiation for Patients (Pts) with Unresected Stage III Non-Small Cell Lung Cancer (NSCLC): Initial Report of Radiation Therapy Oncology Group (RTOG) 9410. Presenter: Walter Curran Affiliation: Bodine Ctr for Cancer Treatment Background: Radiation therapy with or without chemotherapy is standard therapy for locally advanced unresectable non-small cell lung cancer (NSCLC) The use of sequential cisplatin-based chemotherapy followed by thoracic radiation therapy has been shown to be
A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC) Presenter: Joan H. Schulter Affiliation: ECOG Background: Since the initial randomized trials in the early 1990's which showed improved median and overall survival by adding chemotherapy to radiation therapy (RT) in NSCLC patients, several newer agents have been introduced. Some of these agents are used off protocol based on
Impact of Tumor Control on Survival in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Treated with Concurrent Thoracic Radiotherapy (TRT) and Chemotherapy (CT). Presenter: K. Furuse Affiliation: Health Insurance Union Osaka Cent Hosp, Osaka Background: Radiation therapy and chemotherapy is standard therapy in good performance status patients with locally advanced unresectable non-small cell lung cancer (NSCLC) A previously reported study by Furuse et al (J Clin Oncol 1999;17:2692)
An EORTC Randomized Phase III Trial of Three Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer (NSCLC) Presenter: J. P. Van Meerbeeck Affiliation: EORTC Background: Combination chemotherapy improves survival in advanced NSCLC based on numerous reports. Cisplatin based chemotherapy has remained the standard regimen used in most studies. This study was designed to compare 3 different chemotherapy regimens, 2 containing cisplatin and one
Cisplatin/Gemcytobine (CG) vs Cisplatin/Gemcytobine/Vinorelbine (CGV) vs Sequential Doublets of Gemcytobine/Vinorelbine Followed by Ifosfamide/Vinorelbine (GV/IV) in Advanced Non-Small Cell Lung Cancer (NSCLC): Results of a Spanish Lung Cancer Group Phase III Trial Presenter: V. Alberola Affiliation: Spanish Lung Cancer Group Background: The Spanish Lung Cancer Group has found in previous studies that a combination of Gemcytabine/Cisplatin is an effective regimen for the treatment of advanced lung cancer. This study was designed to evaluate this regimen against two other chemotherapy regimens,
Randomized Phase III Study of Amifostine in Patients Treated with Chemoradiation for Inoperable Stage II-III Non-Small Cell Lung Cancer (NSCLC) Presenter: R. Komaki Affiliation: Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX Background The radioprotective property of thiol-containing compounds has been well known for some time. Amifostine(WR-2721) is the most well known of these agents. The proposed mechanism of action is the scavenging of
Concurrent Chemoradiation for Locally Advanced NSCLC in the RTOG Experience: Effect of Overall Treatment Time Presenter: M. Machtay Presenter's Affiliation: University of Pennsylvania Type of Session: Scientific Background A survival advantage has been shown in patients with non small cell lung cancer (NSCLC) with concurrent chemoradiation vs sequential chemoradiation or radiation alone. With concurrent chemoradiation comes increased toxicity, and,
Gemcitabine plus cisplatin (GCis) versus gemcitabine plus carboplatin (GCarb) in patients with stage IIIB and IV non-small cell lung cancer (NSCLC): final results of Czech Lung Cancer Cooperative Group phase III randomized trial Presenter: L. NovakovaPresenter's Affiliation: Czech Lung Cancer Cooperative GroupType of Session: PosterBackground Advanced non-small cell lung cancer has a poor survival. A majority of the patients fail distantly, with metastatic disease. Gemcitabine has been shown to have significant anti-tumor properties against NSCLC, a disease in which
Preliminary report of locally advanced multimodality protocol (LAMP): ACR 427: a randomized phase II study of three chemo-radiation regimens with paclitaxel, carboplatin, and thoracic radiation (TRT) for patients with locally advanced non small cell lung cancer (LA-NSCLC) Presenter: H. ChoyPresenter's Affiliation: ACRType of Session: ScientificBackground The majority of NSCLC patients present with inoperable disease. Therefore, the definitive treatment is with a combination of chemotherapy (most notably platinum containing regimens) and radiation therapy. It has been shown that chemoradiation is more efficacious
Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a phase III study by the Swedish Lung Cancer Study Group (SLUSG) Presenter: C. SederholmPresenter's Affiliation: University Hospital, Linkoping, SwedenType of Session: ScientificBackground Chemotherapy is indicated in patients with locally advanced and metastatic lung cancer who have good performance status and minimal weight loss. The use of combined chemotherapeutic regimens (i.e. doublets) have better
Single-Agent (SA) Versus Combination Chemotherapy (CC) In Advanced Non-Small Cell Lung Cancer (NSCLC): A CALGB Randomized Trial Of Efficacy, Quality Of Life (QoL), And Cost-Effectiveness Presenter: Rogerio C LilenbaumPresenter's Affiliation: CALGBType of Session: PlenaryBackground The standard of care for patients with locally advanced NSCLC and good performance status (PS) is combination chemotherapy (CC). However, while CC has demonstrated increased tumor response rates, these often have not translated to increased overall
Current Role of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Non-Small Cell Lung Cancer (NSCLC): Which Patients and Why Conference Dates: December 4, 2004 Conference Location: Chicago, IL Sponsoring Group: Conference Web Page URL: www.thecbce.com/futureprograms.asp Topics Covered: Overview of EGFR Small-Molecule TKIs, Update on Recent Clinical Data for Small-Molecule TKIs, Second-Line Options for the Treatment of NSCLC, Clinical Variables of Patient Benefit: Who
Current Role of Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitors (TKIs) in Non Small Cell Lung Cancer (NSCLC): Which Patients and Why Conference Date: December 11, 2004 Conference Location: San Francisco, CA Conference Date: January 8, 2005 Conference Location: Atlanta, GA Conference Date: February 5, 2005 Conference Location: Philadelphia, PA Conference Web Page URL: www.thecbce.com/futureprograms.asp Topics Covered: This continuing medical education (CME) activity will
Phase III Trial of Amisfostine with Chemoradiation for Inoperable Non Small Cell Lung Cancer (NSCLC): Does Amifostine Protect Cancer Cells? Presenter: Ritusko KomakiPresenter's Affiliation: MD Anderson Cancer CenterType of Session: ScientificBackground Several randomized studies have proven improved outcomes with chemoradiation vs. radiation alone in the treatment of inoperable NSCLC. More recently, there has been evidence that concurrent chemoradiation is more efficacious than
Treatment of Elderly Non-Small Lung Cancer (NSCLC) Patients with 3 Different Schedules of Weekly Paclitaxel in Combination with Carboplatin: Subanalysis of a Randomized Trial Presenter: S. RamalingamPresenter's Affiliation: University of Pittsburgh Cancer InstituteType of Session: PosterBackground Benefit from combination chemotherapy extends to all age patients with advanced NSCLC Elderly patients with good performance status have comparable efficacy with 'standard' platinum-based doublets. There is concern of
Induction chemotherapy following simultaneous radio/chemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (Stage IIIA/IIIB) Presenter: R. M. HuberPresenter's Affiliation: University of Munich, Germany; BROCAT-GroupType of Session: ScientificBackground Studies of inoperable NSCLC patients have previously shown a small but statistically significant advantage in median survival with combined modality treatment, ie: chemoradiation. This appears to hold true for both
Results of a randomized International Adjuvant Lung Cancer Trial (IALT): cisplatin-based chemotherapy (CT) vs no CT in 1867 patients (pts) with resected non-small cell lung cancer (NSCLC) Presenter: T. LeChevalierPresenter's Affiliation: Institut Gustave RoussyType of Session: PlenaryBackground 1.2 million cases of NSCLC are diagnosed yearly worldwide. 30% of these are resectable but local therapy is not consistently curative. Distant metastases are common. The 1995 MRC lung cancer trial suggested a 5% 5 year OS benefit, but
RTOG 9705, A Phase II Trial of Postoperative Adjuvant Paclitaxel/Carboplatin and Thoracic Radiotherapy in Resected Stage II and IIIA Non-Small Cell Lung Cancer (NSCLC) Patients - Promising Long Term Survival Results Presenter: Mary V. GrahamPresenter's Affiliation: Phelps County Regional Medical CenterType of Session: ScientificBackground The role of adjuvant chemotherapy in addition to radiotherapy (RT) for resected stage II and IIIA NSCLC patients is unclear. A previously published large randomized trial from ECOG showed a lack of benefit of the addition of
CTRT 99/97 A Randomized Trial of Simultaneous Paclitaxel and Radiotherapy vs. Radiotherapy Alone Following Induction Chemotherapy in Stage III Inoperable NSCLC Presenter: Jochen Willner, MDPresenter's Affiliation: BROCATType of Session: ScientificBackground Combined modality chemoradiation is accepted in today's oncologic community as an effective treatment option for unresectable Stage III NSCLC patients, based on the demonstration of a small but significant survival advantage in several phase III
Induction chemotherapy followed by standard thoracic radiotherapy (Std. TRT) vs. hyperfractionated accelerated radiotherapy (HART) for patients with unresectable stage IIIA and B non-small cell lung cancer (NSCLC): Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597) Presenter: Minesh MehtaPresenter's Affiliation: University of Wisconsin/ ECOGType of Session: ScientificBackground The current standard of care for patients with inoperable NSCLC is combined modality chemotherapy and thoracic irradiation. Research is ongoing, however, to establish the optimal scheduling and dose fractionation of the radiation
Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Initial results from intergroup trial 0139 (RTOG 93-09) Presenter: Andrew Turrisi, M.D.Presenter's Affiliation: RTOGType of Session: PlenaryBackground Patients with stage IIIa NSCLC have a poor prognosis. Although definitive chemoradiotherapy (especially when delivered concurrently) remains standard for most patients with pathologic N2 disease, small phase III trials support the use of chemotherapy
Amifostine As Mucosal Protectant in Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving Intensive Chemotherapy and Thoracic Radiotherapy (RT): Results of the Radiation Therapy Oncology Group (RTOG) 98-01 Study Presenter: Maria Werner-Wasik, MDPresenter's Affiliation: Thomas Jefferson UniversityType of Session: ScientificBackground 20-50% of patients receiving thoracic RT with concurrent chemotherapy experience severe esophagitis. Amifostine (AMI) is a radioprotectant that has been shown to improve esophagitis both in animal models and in early clinical
Defining the Future of Chemotherapy in the Treatment of Early-Stage NSCLC Conference Dates: Aug 1 - Oct 31 2005 Conference Location: N/A Telesession Sponsoring Group: The CBCEtm (The Center for Biomedical Continuing Education) Conference Web Page URL: www.thecbce.com Topics Covered: Five-year survival for patients with NSCLC is currently only 15%,largely due to the fact that only approximately half of these patients
Novel Approaches in Stage III NSCLC Presenter: Hak Choy, MD Affiliation: Vanderbilt University School of Medicine The top cause of cancer-related mortality in the United States among both males and females remains lung cancer. Typically, as many as 80% of cases are non-small cell lung cancer, and of these, at least half present as unresectable, locally advanced disease. For
CT-2103 (Xyotax): Phase II Trial of a Polyglutamated Paclitaxel Conjugate in Advanced NSCLC Faculty Disclosure: Howard A. Burris, III, MDbr>In this presentation Dr. Burris discusses the use of CT-2103 for the treatment of lung cancer which has not been approved by the FDA. Presenter: Howard A. Burris, III, MD Affiliation: Sarah Cannon Cancer Center, Nashville, Tennessee CT-2103 (Xyotax, polyglutamated paclitaxel) has many potential
Molecular Prediction of Response and Survival in NSCLC Presenter: Gerold Bepler, MD PhD Affiliation: H. Lee Moffitt Cancer Center Pharmacogenomic research offers the potential for improving upon the results of conventional treatments in managing lung cancer. Currently, the choice of treatment strategy is typically based on site, histopathology, stage, performance status, convenience, and
Optimized Schedule of Weekly Paclitaxel Alone and With Carboplatin: Elderly Advanced NSCLC Patients Presenter: Chandra Belani, MD Affiliation: University of Pittsburgh Lung cancer continues to be the leading cause of cancer death in the United States, with approximately 80% of cases being NSCLC. The overall survival and median survival time in patients with metastatic disease remains dismal. There have been advances in the treatment of both
Erlotinib (Tarceva) and Bevacizumab (Avastin): Combination Therapy for NSCLC Faculty Disclosure: Roy S. Herbst, MDThis presentation by Dr. Herbst will discuss the use of bevacizumab and erlotinib in the treatment of lung cancer which has not been approved by the FDA. Presenter: Roy S. Herbst, MD Affiliation: M.D. Anderson Cancer Center Lung cancer remains a difficult disease to treat, causing the most cancer deaths
Traditional versus up-front 18-FDG PET staging of non-small cell lung cancer (NSCLC): A Dutch Co-operative randomized study Presenter: G.J. HerderPresenter's Affiliation: POORT Study Group, NetherlandsType of Session: ScientificBackground The use of FDG-PET scan as an add-on study in non-small-cell-lung-cancer (NSCLC) patients scheduled to undergo surgery has been shown to be a cost-effective and useful tool in guiding patient management. When employed after
Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) This presentation discusses the use of erlotinib for the treatment of NSCLC which has not been approved by the FDA. Presenter: U. GatzemeierPresenter's Affiliation: TALENT study investigatorsType of Session: ScientificBackground There is a growing body of preclinical data demonstrating the anti-tumor efficacy of erlotinib (OSI-774),
A multicenter, phase III randomized trial for stage IIIb/IV NSCLC of weekly paclitaxel and carboplatin vs. standard paclitaxel and carboplatin given every three weeks, followed by weekly paclitaxel This presentation discusses unapproved dosing schedules for carboplatin and paclitaxel. Presenter: C. P. BelaniPresenter's Affiliation: University of Pittsburg Cancer Institute, Pittsburg, PAType of Session: ScientificBackground Previous trials evaluating standard three week dosing of paclitaxel and carboplatin in stage IIIb/IV NSCLC have
Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC) : 'the "LUCAS" study This presentation discusses off-label use of cetuximab in the treatment of NSCLC. Presenter: R. RosellPresenter's Affiliation: Institut Catala d'Oncologia, Barcelona, SpainType of Session: ScientificBackground The advent of molecular therapeutics and anti-tumor targetted agents has at its center the much discussed and studied epidermal growth
Paclitaxel and gemcitabine vs. carboplatin and gemcitabine. A multicenter, phase III randomized trial in patients with advanced inoperable non-small cell lung cancer (NSCLC) Presenter: P.A. KosmidisPresenter's Affiliation: Hellenic Cooperative Oncology GroupType of Session: ScientificBackground Early phase data has shown the combination of paclitaxel and gemcitabine may be as active and well tolerate as the combination of carboplatin and gemcitabine in patients with inoperable and advanced NSCLC This trial was
A Randomized Phase III Trial Comparing Bexarotene/Carboplatin/Paclitaxel vs. Carboplatin/Paclitaxel in Chemotherapy-Naive Patients with Advanced or Metastatic NSCLC (SPIRIT II Trial) Presenter: G.R. Blumenschein, Jr., MDPresenter's Affiliation: SPIRIT II Trial GroupType of Session: ScientificBackground High RXR-beta expression has been shown to be correlated with increased survival in patients with non-small cell lung cancer (NSCLC). Bexarotene (Targretin) is an RXR-selective rexinoid which forms homodimers and heterodimers
Randomized phase II/III trial of paclitaxel (P) plus carboplatin with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599 Presenter: A.B. SandlerPresenter's Affiliation: Easteran Cooperative Oncology GroupType of Session: PlenaryBackground The standard therapy for patients with advanced NSCLC is platinum-containing doublet chemotherapy. Randomized trials of targeted therapies in chemotherapy-naïve patients with advanced NSCLC have all been negative, including
S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results Presenter: K. PistersPresenter's Affiliation: MD Anderson Cancer CenterType of Session: ScientificBackground Five year Overall Survival (OS) for stages T2NO-T3N1 NSCLC are low, ranging from 9-38%. When this study was designed in the late 1990s, the benefit of adjuvant chemotherapy in resected lung cancer was not yet confirmed. The BLOT trial
Phase III study of concurrent chemortherapy and radiotherapy (CT/RT) vs. CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309) Presenter: Kathy AlbainPresenter's Affiliation: RTOGType of Session: ScientificBackground Patients with stage IIIA NSCLC and N2 (mediastinal) disease have a poor outcome, with long term overall survival consistently reported to be approximately 20% Definitive concurrent chemoradiation is the standard of care in good performance status patients
A Randomized Trial of Radical Surgery versus Thoracic Radiotherapy After Response to Induction Chemotherapy in Patients with Histo-/Cytologically Proven Irresectable Stage IIIA-N2 NSCLC (EORTC 09841) Presenter: J. van MeerbeeckPresenter's Affiliation: EORTC Lung Cancer GroupType of Session: ScientificBackground Stage IIIA non-small cell lung cancer (NSCLC) with stage N2 disease is a heterogeneous group of patients representing 15% of all cases of NSCLC at presentation. Variable treatment approaches have been attempted with 5-year overall
Symptom Response in NSCLC Patients Treated with Erlotinib: QOL Analysis of the NCIC CTG BR.21 Trial Presenter: A. BezjakPresenter's Affiliation: National Cancer Institute CanadaType of Session: ScientificBackground The NCIC CTG BR.21 trial was a randomized phase III trial of Erlotinib (Tarceva) and placebo as second-line therapy for patients with advanced non-small cell lung cancer (NSCLC). 731 previously treated patients who had received 1
A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941) Presenter: J. van MeerbeeckPresenter's Affiliation: University Hospital, Ghent, BelgiumType of Session: PlenaryBackground There remains significant controversy in the optimal treatment of patients with locally advanced stage IIIA NSCLC with ipsilateral mediastinal lymph node involvement (N2). Chemotherapy has shown significant response rates in
ISEL: A Phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens Presenter: N. ThatcherPresenter's Affiliation: Christie Hospital, Manchester, UKType of Session: PlenaryBackground Gefitinib (IRESSA) is an oral medication that acts as a small molecule inhibitor of EGFR. There have been two Phase II trials demonstrating 250 mg/day has activity in pretreated patients with advanced NSCLC, however a survival
ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation in completely resected (stage I-III) non small cell lung cancer (NSCLC) patients (pts) Presenter: R. RosellPresenter's Affiliation: Catalan Institute of Oncology, Badalona, SpainType of Session: PlenaryBackground Recent studies have shown a significant improvement in overall survival with the addition of adjuvant chemotherapy after surgical resection of lung cancer. The ANITA study was designed to evaluate the survival impact of
Percutaneous radiofrequency ablation of primary NSCLC Presenter: M. AmbrogiPresenter's Affiliation: Cardiac and Thoracic Department, Pisa, ItalyType of Session: PlenaryBackground Radiofrequency ablation (RFA) causes local destruction of tumors after insertion of electrodes attached to an RF generator into the mass under CT guidance. RFA works through localized tissue heating causing
Clinical Application of Positron Emission Tomography (PET) in Designing Radiation Fields in Non-Small Cell Lung Cancer (NSCLC) Patients Presenter: Charles G. Wood, MDPresenter's Affiliation: University of Pennsylvania, Dept. of Radiation Oncology, Philadelphia, PAType of Session: ScientificBackground PET scans offer quantitative data regarding the glucose utilization of both tumor and normal tissue. PET scans have become commonplace in the staging of non small cell lung
Use of Postoperative Radiotherapy (PORT) for Resectable Non-Small Cell Lung Cancer (NSCLC). Presenter: J. E. Bekelman, MDPresenter's Affiliation: Memorial Sloan Kettering Cancer Center, NY, NYType of Session: ScientificBackground In 1998, the PORT meta-analysis of nine clinical trials (2128 patients) concluded that when compared to surgery alone, the use of post-operative radiation therapy (PORT) for NSCLC patients with N0 and N1
Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. Presenter: G.M. Strauss Presenter's Affiliation: CALGB Type of Session: Scientific Background Lung cancer is the number one cause of cancer death in America. A meta-analysis published in 1995 demonstrated a marginally significant survival benefit with adjuvant cisplatin based chemotherapy in patients who received surgery for their
Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a phase III trial. Presenter: Minesh P. MehtaPresenter's Affiliation: University of Wisconsin, Madison, WIType of Session: ScientificBackground Motexafin gadolinium (MGd) is a radiosensitizer that is MRI-detectable and selectively localizes in tumors. It can induce redox stress and is an inhibitor of thioredoxin reductase, an enzyme whose overexpression is
Patient Summary: Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Results of a phase III trial Adjuvant chemotherapy in elderly patients: An analysis of National Cancer Institute of Canada Clinical Trials Group and Intergroup BR.10 There have been several studies showing the benefit of chemotherapy in surgically resected non small cell lung cancer (NSCLC). Unfortunately, most studies have limited numbers of elderly patients enrolled in
Patient Summary: Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633 Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. The CALGB 9633 trial randomized patients with stage IB non small cell lung cancer NSCLC to either carboplatin/paclitaxel or no further therapy. This study had been stopped early because the investigators saw a
Motexafin Gadolinium (MGd) Combined With Prompt Whole Brain Radiation Therapy Prolongs Time to Neurologic Progression in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases: Results of a Randomized Phase 3 Trial Presenter: M.P. MehtaPresenter's Affiliation: University of Wisconsin, Madison, WIType of Session: ScientificBackground Motexafin gadolinium (MGd) is a radiosensitizer that is MRI-detectable and selectively localizes in tumors. MGd is an inhibitor of thioredoxin reductase, an enzyme whose overexpression is correlated with poor
Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023. Presenter: Hanna, N.H.Presenter's Affiliation: Indiana University, Indianapolis, INType of Session: ScientificBackground Concurrent platinum-based chemotherapy and thoracic radiation treatment (RT) has become a standard of care in the treatment of unresectable non-small cell lung cancer (NSCLC). This treatment methodology is based on studies
Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023 Scientific Session: Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023 Chemotherapy (containing a platinum drug) combined with chest radiation (RT) has become a standard
Randomized, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) Scientific Session: Randomized, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) Bevacizumab (Avastin), a monoclonal antibody directed against the vascular endothelial growth factor
Motexafin gadolinium (MGd) combined with whole brain radiation therapy prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: Pooled analysis of two randomized phase III trials Presenter: William ShapiroPresenter's Affiliation: Barrow Neurological Institute, Phoenix AZType of Session: ScientificBackground Motexafin gadolinium (MGd) is a radiosensitizer that is MRI-detectable and selectively localizes in tumors. MGd is an inhibitor of thioredoxin reductase, an enzyme whose overexpression is correlated with poor
Outcome After Stereotactic Radiotherapy in 'High-Risk' Patients With Stage I Non-small Cell Lung Cancer (NSCLC) Presenter: F. J. LagerwaardPresenter's Affiliation: VU University Medical Center, Amsterdam, The NetherlandsType of Session: ScientificBackground Surgical treatment with lobectomy or pneumonectomy is recognized as the optimal treatment for stage I non-small cell lung cancer (NSCLC) (Kraev A, Chest, 2007); however, many patients with this
Epidemiology study of never-smokers with non-small cell lung cancer (NSCLC): High percentages of Asian and Hispanic female never-smokers and the significance of Asian ethnicity Epidemiology study of never-smokers with non-small cell lung cancer (NSCLC): High percentages of Asian and Hispanic female never-smokers and the significance of Asian ethnicity Non-small cell lung cancer (NSCLC) remains the number one cause of cancer death in both men and women in the United States. The greatly increased risk of NSCLC development
FLEX: A randomized,multicenter, phase III study of cetuximab in combination with cisplatin/ vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) FLEX: A randomized,multicenter, phase III study of cetuximab in combination with cisplatin/ vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) Epidermal growth factor (EGFR) is over expressed in 80% of lung cancers. Cetuximab is a monoclonal antibody that interferes with
Pain and Rib Fracture after Stereotactic Radiotherapy for Peripheral Non-small Cell Lung Cancer (NSCLC) Presenter: A. M. BradePresenter's Affiliation: Princess Margaret Hospital, Toronto, ON, CanadaType of Session: ScientificBackground The current standard of care for operable patients with early stage lung cancer has been well established as surgical resection +/- adjuvant chemotherapy, with local control rates close to 90%. Treatment
Brachial Plexopathy (BP) from Stereotactic Body Radiotherapy (SBRT) in Early-Stage NSCLC Presenter: J.A. Forquer, MDPresenter's Affiliation: Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, INType of Session: ScientificBackground Brachial plexopathy (BP) is a type of peripheral neuropathy which is caused by impaired function or damage of the brachial plexus, the nerves that control
Reduction of Bone Marrow Suppression for Patients with Stage III NSCLC Treated by Protons and Chemotherapy Compared with IMRT and Chemotherapy Presenter: Ritsuko Komaki, MDPresenter's Affiliation: M.D. Anderson Cancer CenterType of Session: ScientificBackground The concurrent use of chemoradiation is the standard of care for patients with stage III non-small cell lung cancer (NSCLC). Because of the toxicities associated with chemoradiation these patients are at increased risk for bone
Does Proton Beam Radiotherapy (PBT) Reduce Treatment Related Pneumonitis (TRP) Compared to Intensity Modulated Radiation Therapy (IMRT) in Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Concurrent Chemotherapy? Presenter: Ritsuko KOmaki, MD Presenter's Affiliation: M.D. Anderson Cancer Center Type of Session: Scientific Background The risk of radiation pneumonitis limits both the dose of radiation that can be delivered as well as the volume of the thorax that can be treated. It appears that the dose of radiation, the amount of lung radiated, and the
A randomized placebo-controlled phase III study of docetaxel/carboplatin with celecoxib in patients with advanced non-small cell lung cancer (NSCLC): The NVALT-4 study Presenter: Groen, M. M. Hochstenbag, J. W. van Putten, A. Vincent, O. Dalesio, B. Biesma, H. J. Smit, A. Termeer, B. E. van den Borne, F. M. SchramelPresenter's Affiliation: University Medical Center Gron, NetherlandsType of Session: ScientificBackground Cyclooxygenase-2 (COX-2) is an enzyme responsible for the conversion of arachidonic acid
Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC) Title: Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC) Reviewer: Geoffrey Geiger, MD Author(s): M.D. Vincent, C. Butts, L. Seymour, K. Ding, B. Graham, P. Twumasi-Ankrah, D. Gandara, J. Schiller, M. Green,
Reduction of Normal Tissue (NT) Toxicity in Patients with Locally Advanced (LA) NSCLC treated with Concurrent Chemotherapy (ChT) and Proton Beam Therapy (PBT) compared to Intensity Modulated Radiation Therapy (IMRT) Presenter: Ritsuko Komaki, MD Presenter's Affiliation: University of Texas M.D. Anderson Cancer Center Background Lung cancer is the leading cause of cancer mortality with a 5 year overall survival of 15%. Local control with standard photon therapy is less than 50%. Improvements in radiation treatment planning and delivery, in
Proton Beam Therapy Reduced Bone Marrow Suppression Compared with IMRT for Patients with Stage III NSCLC Receiving Concurrent Chemotherapy Presented by: Ritsuko Komaki, MD Presenter's Affiliation: University of Texas M.D. Anderson Cancer Center Background Lung cancer is the leading cause of cancer mortality, with a 5-year overall survival of 15%. Improvements in radiation treatment planning and delivery, in addition to combined modality treatment, have led to an increase
A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19 Presenter: G.D. Goss, MD Affiliation: The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada Background Platinum-based adjuvant chemotherapy in completely resected NSCLC had demonstrated a modest survival benefit of 5% at 5 years when this study was initiated. EGFR expression in NSCLC has been correlated with aggressive morphology and
Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC) Presenter: E. A. Quoix, on behalf of IFCT; Hôpitaux Universitaires, Strasbourg, France Background Lung cancer is the most common cause of cancer mortality in the US, accounting for 30% of cancer-related deaths in men and 26% of cancer-related deaths in women. Non-small cell lung cancer (NSCLC) constitutes approximately 85% of all lung
Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) Presenter: Y. Bang, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. Background Efficacy of conventional chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) appeared to reach a plateau in the mid-1990s, at the same time that targeted therapeutics began to enter clinical trials.
TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy Presenter: S. Lee, University College Hospital/UCL Cancer Institute, London, United KingdomBackground Patients with poor performance status (PS) represent 30-50% of those presenting with advanced (Stage IIIB/IV) NSCLC, and are under-studied. These patients are often not candidates for standard first line chemotherapy (platinum-based doublet
Effect of early palliative care (PC) on quality of life (QOL), aggressive care at the end-of-life (EOL), and survival in stage IV NSCLC patients: Results of a phase III randomized trial Presenter: J. S. Temel, Massachusetts General Hospital, Boston, MA. Background Patients with metastatic NSCLC often have a high symptom burden from the time of initial diagnosis, which greatly affects their quality of life. These patients are often subjected to aggressive care at the end of life, which can contribute to patient distress,
RTOG 0229: A Phase II Trial of Neoadjuvant Therapy with Concurrent Chemotherapy and Full Dose Radiotherapy (XRT) followed by Resection and Consolidative Therapy for LA-NSCLC Authors: M. Suntharalingam, R. Paulus, M. J. Edelman, M. Krasna, W. Burrows, E. Gore, S. S. Yom, H. Choy Institution: University of Maryland School of Medicine, Baltimore, MD; RTOG Statistical Center, Philadelphia, PA; University of Maryland Medical Center, Baltimore, MD; St Joseph's Medical Center, Baltimore, MD; Medical College of Wisconsin,
Treatment of NSCLC patients with proton beam-based stereotactic body radiation therapy: A dosimetric comparison with photon plans highlights the importance of range uncertainty Presenter/Author: Seco, J. Presenter's Affiliation:Massachusetts General Hospital Background Non-small cell lung cancer accounts for 80% of all lung cancers. Surgery is the gold standard and main curative modality for early-stage lung-cancers (T1-T2, N0) and results in favorable treatment outcomes. However, stereotactic body
GILT study: Oral vinorelbine (NVBo) and cisplatin (P) with concomitant radiotherapy (RT) followed by either consolidation (C) with NVBo plus P plus best supportive care (BSC) or BSC alone in stage (st) III non-small cell lung cancer (NSCLC): Final results of a phase (ph) III study Presenter: Rudolf M. Huber, MD, PhD, FCCP Presenter's Affiliation: Medizinische Klinik Innenstadt, München, Germany Background Concurrent chemo-radiotherapy (CT-RT) is considered the standard treatment for patients with stage III NSCLC. Treatment failure in patients with NSCLC, particularly locally advanced NSCLC, is